SUPERVIVENCIA A TRES AÑOS EN UNA COHORTE DE MUJERES CON CÁNCER DE MAMA DE UNA ASEGURADORA EN CALI 2017-2020

Simón Andrés Giraldo oliveros; Diego Alfonso Cardona Gutierrez; Mauricio Rebellon Salazar

doi:10.1590/SciELOPreprints.7283

##article.authors##

Simón Andrés Giraldo oliveros Facultad de Medicina. Fundación Universitaria San Martin Cali, Grupo GISAP
diego alfonso Facultad de Medicina. Fundación Universitaria San Martin Cali, Grupo GISAP https://orcid.org/0009-0004-4464-0146
Mauricio Rebellon Salazar Facultad de Medicina. Fundación Universitaria San Martin Cali, Grupo GISAP https://orcid.org/0009-0006-2854-5821

DOI:

https://doi.org/10.1590/SciELOPreprints.7283

Keywords:

Breast cancer, Survival, Prognosis, Risk factors, Treatment, Stages, Metastasis, Prognostic factors, Follow-up, Survival rate, Clinical factors, Biomarkers, Hormone therapy, Chemotherapy, Radiotherapy, Surgery Quality of life

Abstract

INTRODUCTION: Breast cancer, in particular, is a significant concern in public health due to its high mortality rate. This research focuses on understanding the factors related to the 3-year survival of women with breast cancer in Cali, contributing to addressing this health challenge. OBJECTIVE: To determine the socio-demographic, clinical, and healthcare-related factors associated with the 3-year survival of women with breast cancer affiliated with an insurance provider in Cali from 2017 to 2020. This study aims to generate scientific evidence for decision-making within the insurance provider and the region. METHODOLOGY: A study was conducted in women with breast cancer in Cali to identify factors linked to 3-year survival. Data from a cohort of women with breast cancer affiliated with an insurance provider were analyzed, applying inclusion and exclusion criteria. Socio-demographic, clinical, and healthcare-related factors were assessed. Data were collected from secondary sources and analyzed to determine variables associated with survival. Ethical and confidentiality considerations were adhered to throughout the process. RESULTS: The most significant finding of our study, based on a three-year follow-up of 140 women with breast cancer, is the alarming mortality rate of 21.4%. We emphasize the importance of diagnosing the disease at its early stages, which can make a difference in the survival and prognosis of patients. CONCLUSION: The study highlights the high vulnerability of the cohort of women with breast cancer affiliated with the insurance provider. Although a longer survival time was observed in certain groups, the mortality rate remains significant.